ArticleTherapeutic innovation & regulatory science2026
Identification of Chronic Stress-Related Biomarkers for Potential Diagnosis and Treatment of Osteoporosis: An Integrated Multi-omic and Clinical Data Analysis.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe mechanisms through which chronic stress-related genes influence the diagnosis of osteoporosis (OP), where chronic stress serves as a risk factor, remain unclear. This study aimed to identify chronic stress-related biomarkers using multi-omics approaches and explore their potential applications in the diagnosis and treatment of OP.
methodsBulk RNA sequencing (bulk RNA-seq) and single-cell RNA sequencing (scRNA-seq) data from public databases were integrated. Differential expression analysis, weighted gene co-expression network analysis, and machine learning algorithms (such as receiver operating characteristic curve analysis) were employed to screen candidate biomarkers. A competing endogenous RNA (ceRNA) network and a transcription factor-mRNA (TF-mRNA) regulatory network were constructed to predict targeted drugs. Key cell types and pseudotemporal changes were analyzed via scRNA-seq, and reverse transcription quantitative polymerase chain reaction was used to validate biomarker expression.
resultsTwo highly expressed candidate biomarkers, CD34 and VAMP1, were initially identified, through bioinformatics analysis, but subsequent experimental validation confirmed only CD34 as a robust marker for OP. The ceRNA network comprised 2 mRNAs, 5 miRNAs, and 14 lncRNAs, and predicted 173 TFs. Five potential therapeutic drugs (including botulinum toxin type B and prednisolone) were screened. scRNA-seq revealed B cells and T cells as key cell types, with CD34 showing dynamic expression during B cell differentiation.
conclusionThis study systematically elucidates the role of chronic stress-related biomarkers in OP, providing novel diagnostic targets (CD34) and predicting potential therapeutic agents. Although VAMP1 showed diagnostic potential in silico, its lack of validation underscores the need for larger cohort studies. Analysis at the single-cell level provides a preliminary landscape to explore potential cell types and differentiation mechanisms, offering a theoretical foundation for the precise diagnosis and treatment of OP.
Indexed as
Identifiers
42265416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.